Numéro tarifaire 3004900000 80 - autres

Estimer le coût d’importation pour 300490

Simple estimation. La valeur en douane est le prix incluant le transport et l’assurance jusqu’à la frontière de l’UE. Les accises, autres redevances et droits antidumping propres à un producteur ne sont pas inclus. Les taux préférentiels exigent une preuve d’origine valable. Groupes de pays et exclusions : TARIC, au novembre 2026.

Mesures à l’exportation pour 3004900000

Ce qui s’applique quand ces marchandises quittent l’UE : contrôles à l’exportation, autorisations (biens à double usage et autres), interdictions par destination et unité supplémentaire de la déclaration d’exportation.

Historique

Règles d’origine préférentielles pour 3004900000

Ce que la marchandise doit remplir pour être originaire d’un pays partenaire et bénéficier du droit préférentiel, par accord. Texte des accords en anglais.

• EU-Algeria Association Agreement · Algérie

  EU-Egypt Association Agreement · Égypte

  EU-Morocco Association Agreement · Maroc

  Medicaments (excluding goods of heading 3002, 3005 or 3006):

  – Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

• Generalised Scheme of Preferences (GSP, GSP+, EBA) · Arménie, Îles Salomon, Inde, Kenya, Pakistan, Samoa, Syrie, Viêt Nam

  EU-Singapore FTA · Singapour

  Pharmaceutical products / or: Manufacture from materials of any heading

• Autonomous Trade Preferences (Western Balkans) · Kosovo

  Medicaments (excluding goods of heading 3002, 3005 or 3006):

  - Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  - Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EU-Canada CETA · Canada

  A change from within any one of these subheadings or any other subheading.

• EU-Chile Association Agreement · Chili

  Medicaments (excluding goods of heading 3002, 3005 or 3006): — Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 or 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 or 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EU-Colombia/Peru/Ecuador Trade Agreement · Colombie, Équateur, Pérou

  Medicaments (excluding products of heading 3002, 3005 or 3006):

  Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product

  Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 per cent of the ex-works price of the product

• EPA CARIFORUM

  Medicaments (excluding goods of heading No 3002, 3005 or 3006): – Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product – Other / or: Manufacture in which: – all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product; – the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EPA Eastern and Southern Africa

  – Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex works price of the product

• EU Market Access Regulation (EPA) · Cameroun, Côte d’Ivoire, Ghana, Kenya

  Medicaments (excluding goods of heading No 3002, 3005 or 3006):

  – Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used is classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product

  – Other / or: Manufacture in which: all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product; the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EPA Pacific · Fidji, Îles Salomon, Papouasie-Nouvelle-Guinée, Samoa

  Medicaments (excluding goods of heading No 3002, 3005 or 3006): – Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex works price of the product

• EU-Israel Association Agreement · Israël

  Medicaments (excluding goods of heading Nos 3002, 3005 and 3006) / or: Manufacture in which: all the materials used are classified within a heading other than that of the product. However, materials of heading Nos 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product, and the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EU-Jordan Association Agreement · Jordanie

  Medicaments (excluding goods of heading 3002, 3005 or 3006): - Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EU-Japan EPA · Japon

  CTSH; A chemical reaction, purification, mixing and blending, production of standard materials, a change in particle size, isomer separation or biotechnological processing is undergone; MaxNOM 50 % (EXW); or RVC 55 % (FOB).

• EU-Korea FTA · Corée du Sud

  Pharmaceutical products; except for: / or: Manufacture from materials of any heading, except that of the product. However, materials of the same heading as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

• EU-Central America Association Agreement

  Medicaments (excluding goods of heading 3002, 3005 or 3006): / or: Manufacture from materials of any heading, except that of the product and heading 3003

• EU-Lebanon Association Agreement · Liban

  Medicaments (excluding goods of heading 3002, 3005 or 3006):

  – Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – Other / or: Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EU-Mexico Global Agreement · Mexique

  Medicaments (excluding goods of heading No 3002, 3005 or 3006): — Obtained from amikacin of heading No 2941 / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product — Other / or: Manufacture in which: all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex-works price of the product, the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EU-Palestine Interim Association Agreement · Palestine

  Medicaments (excluding goods of heading No 3002, 3005 or 3006): - Obtained from amikacin of heading No 2941 - Other / or: Manufacture in which all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20 % of the ex works price of the product Manufacture in which: all the materials used are classified within a heading other than that of the product. However, materials of heading No 3003 or 3004 may be used provided their value, taken together, does not exceed 20% of the ex-works price of the product; the value of all the materials used does not exceed 50% of the ex-works price of the product

• EU-Tunisia Association Agreement · Tunisie

  Medicaments (excluding goods of heading 3002, 3005 or 3006): Obtained from amikacin of heading 2941 / or: Manufacture from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Manufacture: from materials of any heading, except that of the product. However, materials of headings 3003 and 3004 may be used, provided that their total value does not exceed 20 % of the ex-works price of the product, and in which the value of all the materials used does not exceed 50 % of the ex-works price of the product

• EU-Viet Nam FTA · Viêt Nam

  Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or in forms of packing for retail sale. / or: Manufacture from materials of any heading, except that of the product; or manufacture in which the value of all the materials used does not exceed 70 % of the ex-works price of the product.

Source : Commission européenne, Access2Markets (CC BY 4.0, abrégé). Seul le texte de l’accord fait foi. Access2Markets

Notes légales et notes explicatives pour 3004900000

Sources : nomenclature combinée 2026, annexe I du règlement (CEE) nº 2658/87 (CELEX 32025R1926), et notes explicatives de la nomenclature combinée (CELEX 02019XC0329(02)-20260213). Les notes de section et de chapitre ont force juridique ; les notes explicatives sont une aide à l’interprétation. EUR-Lex

Règlements de classement de l’UE pour 3004900000

Règlements de la Commission qui ont classé des marchandises précises sous ce code. Ils lient les douanes de tous les États membres pour des marchandises identiques.

• 3004 90 00 8 juin 2016 · Règlement sur EUR-Lex
  Un produit conditionné pour la vente au détail sous la forme de capsules de gélatine, constituées chacune (en mg) de:

  — siméthicone: 257,5, — gélatine, glycérol, diméthicone, dioxyde de titane (E 171), sorbate de potassium, colorants alimentaires E 110 et E 122: environ 196. Le produit calme les douleurs d'estomac et prévient les ballonnements et flatulences. Selon l'étiquette, il est destiné à la consommation humaine et la dose journalière recommandée est d'une à deux capsules après chaque repas principal.

  Motifs

  Le classement est déterminé par les règles générales 1 et 6 pour l'interprétation de la nomenclature combinée, par la note 1 f) du chapitre 21 et par le libellé des codes NC 3004 et 3004 90 00 . Du fait de la présence de siméthicone, le produit présente des propriétés thérapeutiques. Son classement dans la position 2106 en tant que préparation alimentaire non dénommée ni comprise ailleurs est dès lors exclu [voir note 1 f) du chapitre 21]. Le produit est conditionné pour la vente au détail sous forme de doses et présente des propriétés prophylactiques ou thérapeutiques clairement définies, par exemple contre la dyspepsie fonctionnelle. Il convient dès lors de classer le produit en tant que médicament conditionné pour la vente au détail sous forme de doses sous le code NC 3004 90 00 .

• 3004 90 00 28 nov. 2013 · Règlement sur EUR-Lex
  Le produit est conditionné pour la vente au détail sous forme de comprimés, chaque comprimé, d'un poids total d'environ 900 mg, étant constitué (en mg):

  — d'acide alpha-lipoïque (300), — de calcium (sous forme de phosphate de calcium dibasique) (88,5), — de cellulose microcristalline, d'éthylcellulose hydroxypropylique, de dioxyde de silicium colloïdal et de stéarate de magnésium (environ 511). Selon l’étiquette, le produit est présenté comme un complément alimentaire destiné à la consommation humaine. La dose journalière recommandée figurant sur l’étiquette est d’un comprimé par jour.

  Motifs

  Le classement est déterminé par les dispositions des règles générales 1 et 6 pour l'interprétation de la nomenclature combinée, ainsi que par le libellé des codes NC 3004 et 3004 90 00 . Bien que le produit soit présenté comme un complément alimentaire, il a des effets dans le domaine de la prévention ou du traitement de maladies ou d’affections. Son classement dans la position 2106 en tant que préparation alimentaire non dénommée ni comprise ailleurs est dès lors exclu [voir aussi les notes explicatives du système harmonisé relatives à la position 2106 , point 16)]. Le produit est conditionné pour la vente au détail sous forme de doses et présente des propriétés prophylactiques ou thérapeutiques clairement définies, par exemple contre la polyneuropathie. Il doit dès lors être classé comme un médicament présenté sous forme de doses pour la vente au détail de la position 3004 .

Renseignements tarifaires du Royaume-Uni pour 3004900000

Décisions de HM Revenue & Customs pour des marchandises dont le code britannique commence comme ce code de l’UE. Le tarif britannique diffère de celui de l’UE : ces décisions ne sont qu’une indication pour l’UE.

• UK 3004900000 Valable du 5 déc. 2023 au 4 déc. 2026 · Décision 600009155 sur GOV.UK

  Biofreeze Pain Relieving Gel Ingredients: Isopropyl Alcohol, Water, Herbal Extract (IIex paraguariensis), Carbomer, Triethanolamine, Menthol, Camphor, Silicon Dioxide, Methylparaben, Glycerine, Propylene Glycol, FD&C yellow #5, FD&C blue #1 For the temporary relief of minor aches and pains of muscles and joints associated with arthritis pain, backache, strains and sprains. Packaging: 112gr/118ml tube

  Justification

  Classification has been determined in accordance with the following:- For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)). General Interpretative Rules (GIR)s GIR 1 has been used to classify this product by the terms of heading 3004 - Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale GIR 5b has been used to identify the type of packaging – 112gr/118ml tube GIR 6 has been used to classify the goods to subheading level 300490 – Other than elsewhere specified Also classified in accordance with: Chapter 30 additional note 1 Section note 2 HSEN to 3004

• UK 3004900000 Valable du 5 déc. 2023 au 4 déc. 2026 · Décision 600009181 sur GOV.UK

  Biofreeze Pain Relieving Gel roll-on Ingredients: Isopropyl Alcohol, Water, Herbal Extract (IIexparaguariensis),Carbomer, Triethanolamine, Menthol, Camphor, Silicon Dioxide, Methylparaben, Glycerine, Propylene Glycol, FD&C yellow #5,FD&C blue #1 For the temporary relief of minor aches and pains of muscles and joints associated with arthritis pain, backache, strains and sprains Packaging: 84gr/89ml

  Justification

  Classification has been determined in accordance with the following:- For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)). General Interpretative Rules (GIR)s GIR 1 has been used to classify this product by the terms of heading 3004 - Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale GIR 5b has been used to identify the type of packaging – 84gr/89ml GIR 6 has been used to classify the goods to subheading level 300490 – Other than elsewhere specified Also classified in accordance with: Chapter 30 additional note 1 Section note 2 HSEN to 3004

• UK 3004900000 Valable du 5 déc. 2023 au 4 déc. 2026 · Décision 600009182 sur GOV.UK

  Biofreeze Spray Ingredients: Ethanol, Arnica Montana, Calendula, Chamomile, DimethylSulfone, Echinacea, Menthol, Ilex Paraguariensis, IsopropylMyristate, Juniper Berry, Purified Water USP, White Tea For the temporary relief of minor aches and pains of muscles and joints associated with arthritis pain, backache, strains and sprains Packaging: 104gr/118ml

  Justification

  Classification has been determined in accordance with the following:- For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)). General Interpretative Rules (GIR)s GIR 1 has been used to classify this product by the terms of heading 3004 - Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale GIR 5b has been used to identify the type of packaging – 104gr/118ml GIR 6 has been used to classify the goods to subheading level 300490 – Other than elsewhere specified Also classified in accordance with: Chapter 30 additional note 1 Section note 2 HSEN to 3004

Source : HM Revenue & Customs, Advance Tariff Rulings. Contient des informations du secteur public sous licence Open Government Licence v3.0.

Commerce de l’UE en 2025 pour 300490

Importations extra-UE

43,7 Md €

228 170 t

Exportations extra-UE

131,2 Md €

Principaux pays d’origine selon la valeur importée

1. Suisse 16,9 Md €
2. États-Unis 14 Md €
3. Royaume-Uni 5,4 Md €
4. Inde 2 Md €
5. Canada 1,3 Md €

Codes NC8 sous ce code : 1. Source : Eurostat, Comext, CC BY 4.0, traité par hscode.info. Le commerce confidentiel n’est pas attribué aux codes.

Changement du SH 2028

D’après les tables de correspondance de l’OMD du SH 2022 au SH 2028, à titre indicatif. L’UE fixe elle-même ses codes NC pour 2028.

Droit d’importation au Royaume-Uni pour 300490

• 0%

Droits de pays tiers de tous les codes britanniques sous cette sous-position du SH. Source : UK Department for Business and Trade, au 2 nov. 2026. Le tarif britannique diffère du tarif de l’UE.

TVA à l’importation dans l’UE

• Allemagne 19 %
• Autriche 20 %
• Belgique 21 % éventuellement 6 %
• Bulgarie 20 %
• Chypre 19 % éventuellement 5 %
• Croatie 25 % éventuellement 5 %
• Danemark 25 %
• Espagne 21 %
• Estonie 24 % éventuellement 9 %
• Finlande 25,5 % éventuellement 13,5 %
• France 20 % éventuellement 2,1 %, 10 %
• Grèce 24 % éventuellement 6 %, 13 %
• Hongrie 27 %
• Irlande 23 %
• Italie 22 % éventuellement 10 %
• Lettonie 21 % éventuellement 12 %
• Lituanie 21 % éventuellement 5 %
• Luxembourg 17 % éventuellement 3 %
• Malte 18 %
• Pays-Bas 21 % éventuellement 9 %
• Pologne 23 %
• Portugal 23 % éventuellement 6 %
• Roumanie 21 % éventuellement 11 %
• Slovaquie 23 % éventuellement 5 %
• Slovénie 22 % éventuellement 9,5 %
• Suède 25 %
• Tchéquie 21 % éventuellement 12 %

Taux normal par État membre, sur la valeur en douane, les droits et le transport jusqu’à destination. Les taux réduits dépendent souvent de l’usage ou de l’acheteur et ne s’appliquent que si le pays les prévoit pour ces marchandises. Source : Commission européenne, Taxes in Europe Database, au 2 nov. 2026.

Règles d’origine

Informations

Structure du HS-Code

Arborescence HS-Code